Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 7/2011

01.07.2011 | Article

Use of procalcitonin (PCT) to guide discontinuation of antibiotic use in an unspecified sepsis is an antimicrobial stewardship program (ASP)

verfasst von: Y. X. Liew, M. P. Chlebicki, W. Lee, L. Y. Hsu, A. L. Kwa

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Clinicians have used procalcitonin (PCT) (biomarker to differentiate bacterial from non-bacterial sepsis) to guide use of antibiotics in patients. As the data for utility of PCT to discontinue antibiotics in an antimicrobial stewardship program (ASP) are lacking, we aim to describe the outcomes of patients in whom PCT was used to discontinue antibiotics under our ASP. An antimicrobial stewardship (AS) team intervened to discontinue antibiotics in patients with persistent fever or leucocytosis, source of sepsis unknown or negative bacteriological cultures, who had completed an adequate course of antibiotic therapy and had a PCT of <0.5 μg/L. Main outcomes evaluated were 14-day re-infection, 30-day mortality and readmission. Antibiotic therapy was discontinued in 42 patients in 1 year. Unknown source of sepsis was found in 38% of the patients (including possible malignant fever) and culture-negative pneumonia was found in 21%. Two patients died of advanced cancer. One patient decided for comfort care and died one week later. One patient died due to a second episode of pneumonia 37 days after first PCT test. Six patients were readmitted within 30 days due to non-infectious causes. Three patients were readmitted due to culture-negative pneumonia. None had a 14-day re-infection. PCT used to discontinue antibiotics under our ASP did not compromise patients’ outcome.
Literatur
1.
Zurück zum Zitat Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J (2009) Bad bugs need drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12PubMedCrossRef Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J (2009) Bad bugs need drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12PubMedCrossRef
2.
Zurück zum Zitat Slama TG, Amin A, Brunton SA et al. (2005) A clinician's guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria. Am J Med 118(Suppl 7A):1–6 Slama TG, Amin A, Brunton SA et al. (2005) A clinician's guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria. Am J Med 118(Suppl 7A):1–6
3.
Zurück zum Zitat Larson E (2007) Community factors in the development of antibiotic resistance. Annu Rev Public Health 28:435–447 Larson E (2007) Community factors in the development of antibiotic resistance. Annu Rev Public Health 28:435–447
4.
Zurück zum Zitat Sehulster L, Chinn RY, CDC, HICPAC (2003) Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR 52(rr10):1–42 Sehulster L, Chinn RY, CDC, HICPAC (2003) Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR 52(rr10):1–42
5.
Zurück zum Zitat Fraser GL, Stogsdill P, Dickens JD, Wennberg DE, Smith RP, Prato BS (1997) Antibiotic optimization. An evaluation of patient safety and economic outcomes. Arch Intern Med 157:1689–1694PubMedCrossRef Fraser GL, Stogsdill P, Dickens JD, Wennberg DE, Smith RP, Prato BS (1997) Antibiotic optimization. An evaluation of patient safety and economic outcomes. Arch Intern Med 157:1689–1694PubMedCrossRef
6.
Zurück zum Zitat Harbarth S, Holeckova K, Froidevaux C et al (2001) Geneva Sepsis Network. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 164(3):396–402PubMed Harbarth S, Holeckova K, Froidevaux C et al (2001) Geneva Sepsis Network. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 164(3):396–402PubMed
7.
Zurück zum Zitat Nobre V, Harbarth S, Graf JD et al (2008) Use of PCT to shorten antibiotic treatment duration in septic patients. Am J Respir Crit Care Med 177(5):498–505PubMedCrossRef Nobre V, Harbarth S, Graf JD et al (2008) Use of PCT to shorten antibiotic treatment duration in septic patients. Am J Respir Crit Care Med 177(5):498–505PubMedCrossRef
8.
Zurück zum Zitat Christ-Crain M, Jaccard-Stolz D, Bingisser R et al (2004) Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363:600–607PubMedCrossRef Christ-Crain M, Jaccard-Stolz D, Bingisser R et al (2004) Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363:600–607PubMedCrossRef
9.
Zurück zum Zitat Christ-Crain M, Stolz D, Bingisser R et al (2006) Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 174:84–93PubMedCrossRef Christ-Crain M, Stolz D, Bingisser R et al (2006) Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 174:84–93PubMedCrossRef
10.
Zurück zum Zitat Stolz D, Christ-Crain M, Bingisser R et al (2007) Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 131:9–19PubMedCrossRef Stolz D, Christ-Crain M, Bingisser R et al (2007) Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 131:9–19PubMedCrossRef
11.
Zurück zum Zitat Briel M, Schuetz P, Mueller B et al (2008) Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 168:2000–2007PubMedCrossRef Briel M, Schuetz P, Mueller B et al (2008) Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 168:2000–2007PubMedCrossRef
12.
Zurück zum Zitat Bouadma L, Luyt CE, Tubach F et al (2010) Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375:463–474PubMedCrossRef Bouadma L, Luyt CE, Tubach F et al (2010) Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375:463–474PubMedCrossRef
Metadaten
Titel
Use of procalcitonin (PCT) to guide discontinuation of antibiotic use in an unspecified sepsis is an antimicrobial stewardship program (ASP)
verfasst von
Y. X. Liew
M. P. Chlebicki
W. Lee
L. Y. Hsu
A. L. Kwa
Publikationsdatum
01.07.2011
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 7/2011
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-011-1165-6

Weitere Artikel der Ausgabe 7/2011

European Journal of Clinical Microbiology & Infectious Diseases 7/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.